Artichoke Capital

Artichoke Capital is a small Singapore-based firm that operates at the frontier-tech end of venture, with a stated focus on Web3, blockchain, crypto, AI infrastructure, and fintech. Healthcare is not part of the investment scope, and physician founders should treat this fund as a low-priority option unless their company genuinely sits at the intersection of decentralized infrastructure or AI compute and a healthcare-adjacent application.

The thesis is unapologetically frontier. Artichoke backs early-stage teams building protocol-level infrastructure, crypto-native applications, and the AI tooling that supports them. Sapien and Notifi are two of the portfolio companies the firm references publicly, both of which sit in the Web3 application layer rather than in healthcare. That portfolio shape signals where the fund’s diligence muscle and follow-on conviction actually live, and it is not in clinical software, diagnostics, or medical devices.

Check size is undisclosed but, given the firm’s size and the typical economics of crypto-native seed rounds, founders should assume modest co-investment checks rather than lead-investor commitments. Stage runs from seed through Series B, with the bulk of activity concentrated at the earlier end. Geography is global in principle but Asia-anchored in practice, with Singapore as the operational hub. Founders building in Asian markets, or building for Asian crypto and frontier-tech ecosystems, will find the most natural fit.

Shawn Lim is the founder and partner who runs the firm and is the single point of contact for new opportunities. The decision-making structure is compact, which means a yes or a no will come quickly once the conversation is real.

The approach guidance for Artichoke is narrow. If you are a physician founder building a pure clinical or healthcare-software business, this is not the right fund and a pitch will not land. If, however, you are building decentralized health-data infrastructure, an AI-compute layer with a healthcare application, a tokenized clinical-research network, or another genuinely frontier-tech product where the underlying technology is the wedge and healthcare is the application surface, there is a thin but real path to a conversation. Reach Shawn through Singapore-based crypto and AI operators, or through frontier-tech accelerators that Artichoke is connected to. Avoid pitching at the wellness or consumer-health layer; the fund is technical, not consumer. Time the conversation when you have working code, a credible technical team, and a clear answer to the question of why a frontier-tech architecture is necessary rather than decorative for your healthcare use case.